Boston Common Asset Management LLC Raises Holdings in Eli Lilly and Company $LLY

Boston Common Asset Management LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 31.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 35,763 shares of the company’s stock after purchasing an additional 8,468 shares during the quarter. Boston Common Asset Management LLC’s holdings in Eli Lilly and Company were worth $27,878,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in LLY. Family CFO Inc acquired a new position in Eli Lilly and Company during the second quarter worth $54,000. Duquesne Family Office LLC boosted its stake in Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after buying an additional 32,640 shares during the last quarter. Corient IA LLC acquired a new position in Eli Lilly and Company during the first quarter worth $570,000. Cutter Capital Management LP acquired a new position in Eli Lilly and Company during the first quarter worth $14,866,000. Finally, Emerald Advisors LLC boosted its stake in Eli Lilly and Company by 60.8% during the second quarter. Emerald Advisors LLC now owns 1,021 shares of the company’s stock worth $796,000 after buying an additional 386 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY opened at $840.46 on Friday. The stock’s 50-day moving average price is $734.60 and its 200 day moving average price is $765.98. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market cap of $795.47 billion, a price-to-earnings ratio of 54.93, a PEG ratio of 1.17 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the company earned $3.92 EPS. Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity

In related news, CEO David A. Ricks purchased 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last quarter. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Guggenheim decreased their price target on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Finally, Morgan Stanley decreased their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $938.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.